AstraZeneca divests Seroquel rights: US and Canada

3 December 2019 07:00 GMT

 

AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada

 

Sale to Cheplapharm supports AstraZeneca's focus on main therapy areas

 

AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in the US and Canada to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the US and Canada.

 

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: "This divestment supports our strategy of reducing the number of mature medicines to enable reinvestment in our main therapy areas. Cheplapharm recently agreed to acquire the commercial rights to Seroquel and Seroquel XR in most European markets and Russia from AstraZeneca and this new agreement will help ensure continued patient access to this important established medicine in North America as well."

 

AstraZeneca will continue to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period.

 

Financial considerations

Cheplapharm will make an upfront payment of $35m to AstraZeneca and may also make future sales-contingent payments of up to $6m. Income arising from the upfront and future payments will be reported in AstraZeneca's financial statements within Other Operating Income & Expense. In 2018, Seroquel generated sales of $36m in the markets covered by this agreement, while Seroquel XR generated $79m. The agreement does not impact the Company's financial guidance for 2019. As there were no closing conditions to the divestment, the agreement became effective upon signing.

 

Pursuant to Listing Rule 10.4.1R (notification of class 2 transactions), the gross book value of assets subject to the divestment as at 31 December 2018 was nil. In the year to 31 December 2018, the aggregate profit before tax attributable to Seroquel and Seroquel XR in the relevant territories were $108m. The consideration will be paid in cash and the proceeds used for general corporate purposes.

 

About Seroquel

Seroquel and Seroquel XR are atypical anti-psychotic medicines with antidepressant properties. The main indications for Seroquel are the treatment of schizophrenia and bipolar disorder. Seroquel XR is also approved in some markets for major depressive disorder and generalised anxiety disorder.

 

AstraZeneca previously divested the rights to Seroquel and Seroquel XR in the UK, Japan and other major international markets. AstraZeneca also agreed to divest the rights to the medicines in Europe (excluding the UK) and Russia to Cheplapharm earlier in 2019, a transaction that is expected to complete in the fourth quarter of 2019, subject to customary closing conditions and regulatory clearances.

 

About AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).

Media Relations    
Gonzalo Viña   [phone]
Rob Skelding Oncology [phone]
Rebecca Einhorn Oncology [phone]
Matt Kent BioPharmaceuticals [phone]
Jennifer Hursit Other [phone]
Christina Sweden [phone]
Malmberg
Hägerstrand
Michele Meixell US [phone]
     
Investor    
Relations
Thomas Kudsk   [phone]
Larsen
Henry Wheeler Oncology [phone]
Christer BioPharmaceuticals [phone]
Gruvris (Cardiovascular, Metabolism)
Nick Stone BioPharmaceuticals (Renal) [phone]
Environmental, Social and
Governance
Josie Afolabi BioPharmaceuticals [phone]
(Respiratory) Other medicines
Craig Marks Finance Fixed income [phone]
Jennifer Corporate access Retail [phone]
Kretzmann investors
US toll-free   [phone]

 

Adrian Kemp
Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

https://news.cision.com/astrazeneca/r/astrazeneca-divests-seroquel-rights--us-and-canada,c2980621

https://mb.cision.com/Main/309/2980621/1154540.pdf

(c) 2019 Cision. All rights reserved., source Press Releases - English